ADVERTISEMENT
Search
Login JOIN / RENEW

Transitions Magazine

Transitions is published bi-monthly for members of the APhA New Practitioner Network. The online newsletter contains information focused on life inside and outside pharmacy practice, providing guidance on various areas of professional, personal, and practice development. Each issue includes in-depth articles on such topics as personal financial management, innovative practice sites, career profiles, career development tools, residency and postgraduate programs, and more.

FDA warns of dental problems associated with certain buprenorphine... FDA warns of dental problems associated with certain buprenorphine...

FDA warns of dental problems associated with certain buprenorphine...

0 25486

FDA is drawing attention to dental problems linked to buprenorphine-containing medications that are dissolved under the tongue or placed against the inside of the cheek to treat opioid use disorder and pain.

FDA puts clozapine REMS requirements on temporary hold FDA puts clozapine REMS requirements on temporary hold

FDA puts clozapine REMS requirements on temporary hold

FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.

0 30855
New impurities lurking in some heart medications New impurities lurking in some heart medications

New impurities lurking in some heart medications

Over the past few years, blood pressure medications have been recalled due to concerns about N-nitrosodimethylamine (NDMA), a probable carcinogen....
0 29491
FDA takes steps to improve quality, safety of sunscreens FDA takes steps to improve quality, safety of sunscreens

FDA takes steps to improve quality, safety of sunscreens

FDA is working to improve the quality, safety, and efficacy of sunscreens as part of its implementation of new authorities for certain OTC drugs.
0 35692

Tocilizumab in short supply due to pandemic

Some individuals with rheumatoid arthritis (RA) are treated with a monthly infusion of the biologic tocilizumab (Actemra—Genentech). However, the drug is now in short supply because of the surge in COVID-19 cases.

12
ADVERTISEMENT